Captivision Inc Ordinary Shares CAPT 深 沪
已收盘 08-15 16:00:00 美东时间
1.31
+0.050
+3.97%
华盛通- 最 高1.3199
- 今 开1.28
- 成交量 5.56万股
- 最 低 1.2519
- 昨 收 1.26
- 总市值 4800.30万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.3703
- 委 比 -93.21%
- 总股本 3664.35万
- 历史最高 7.919
- 量 比 0.39
- 振 幅 5.40%
- 历史最低 0.3703
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Profound Medical预计2025年营收增长70%-75%
美股周五早盘，Profound Medical（PROF）股价下跌6%，该公司预计2025年营收增长70%-75%，主要得益于其TULSA-AI技术和CA...
08-15 22:31
Captivision Inc. Faces Uncertainty After Auditor Resignation
Captivision Inc ( ($CAPT) ) has shared an announcement. On August 1, 2025, Capt...
08-08 06:10
Captivision Accelerates Strategic Transformation Featuring Asset-Light Focus
Captivision Inc. announced a strategic transformation to optimize resources and focus on high-growth LED markets. The company is exploring strategic options for its Korean subsidiary, including divestiture, to transition to an asset-light model. Key growth areas include sports/entertainment LED solutions, commercial applications, and technology innovation. The transformation aims to improve capital efficiency, margins, and agility, positioning Ca...
08-07 21:30
Captivision, Inc. Announces Extension Granted by Nasdaq to Regain Compliance with Periodic Filing Requirement
Captivision Inc. has secured approval from the Nasdaq Hearings Panel to continue listing on the Nasdaq, contingent on meeting certain conditions tied to its efforts to comply with the Periodic Filing Rule. The company is collaborating with its auditor, KPMG, to finalize restated financials and aims to submit its 2024 Annual Report by September 30, 2025. It must provide an audit update by August 29 and demonstrate full compliance by October 15. Wh...
07-29 12:00
Purple Biotech's Chief Executive Officer Gil Efron Issued A Letter To Shareholders Highlighting The Company's Scientific Progress, Operational Execution, And Strategic Milestones During 1H 2025
2025 First Half HighlightsCM24 (α-CEACAM1 monoclonal antibody)Our Phase 2 dataset demonstrated strong objective response rates (ORR) in biomarker-enriched subgroups of second line PDAC patients, as outlined below. These
07-24 19:29
Captivision, Inc. Announces Compliance with Nasdaq’s Market Value of Listed Securities and Minimum Bid Price Requirements
Captivision Inc. announced compliance with Nasdaq's market value and minimum bid price rules as of July 11, 2025. However, it remains non-compliant with Listing Rule 5250(c)(1) due to a delayed Form 20-F filing. The company plans to present its compliance plan at a July 22 hearing before the Nasdaq Panel. There is no assurance the Panel will grant further extensions or that compliance will be achieved by any extended deadline.
07-15 12:00
Captivision and digiLED Complete Phase One of Landmark LED Installations at Canary Wharf
Captivision Inc. announces the successful completion of Phase One of a multi-phase LED signage installation project in partnership with digiLED and Canary Wharf Group. This milestone marks Canary Wharf's transformation into one of the world's most advanced digital commercial districts, featuring large-format digital billboards, interactive kiosks, and architectural LED signage. The project lays the foundation for a new era of communication and co...
06-27 12:00
Purple Biotech Presents New Preclinical Data On CAPTN-3 Tri-Specific Antibody Platform At EACR 2025
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced
06-23 19:06
12 Industrials Stocks Moving In Monday's Intraday Session
Gainers Hong Kong Pharma Digital (NASDAQ:HKPD) shares increased by 25.6% to $2...
06-10 01:06
